title: Correlation between cidofovir-associated uveitis and failing immunorestoration during HAART.
abstract: In order to elucidate the factors related to the development of cidofovir-associated uveitis in AIDS patients receiving highly active antiretroviral therapy, the characteristics of 17 AIDS patients with Cytomegalovirus retinitis ( n=10) or progressive multifocal leukoencephalopathy ( n=7) treated with intravenous cidofovir were evaluated. Six cases of cidofovir-associated uveitis occurred among the patients with retinitis. No cases were detected among the patients with progressive multifocal leukoencephalopathy. Stepwise linear regression analysis revealed a significantly higher HIV-viremia level ( P=0.01) and a significantly lower CD4+ cell count ( P=0.009) among cases at the time of uveitis onset in comparison with patients who did not develop uveitis. Thus, cidofovir-associated uveitis seems to occur more frequently in AIDS patients with retinitis in whom highly active antiretroviral therapy fails to restore immunity.
authors.affiliation: Department of Infectious Diseases, Catholic University, Rome, Italy. etaccone@caregroup.harvard.edu
authors.forename: E
authors.initials: E
authors.lastname: Tacconelli
authors.forename: M
authors.initials: M
authors.lastname: Tumbarello
authors.forename: R
authors.initials: R
authors.lastname: Rabagliati
authors.forename: G
authors.initials: G
authors.lastname: Scoppettuolo
authors.forename: A
authors.initials: A
authors.lastname: Minnella
authors.forename: G
authors.initials: G
authors.lastname: Ventura
authors.forename: R
authors.initials: R
authors.lastname: Cauda
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology*; D000328:Adult; D000704:Analysis of Variance; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects* / Q000379:methods; D016022:Case-Control Studies; D000077404:Cidofovir; D015331:Cohort Studies; D016001:Confidence Intervals; D003596:Cytosine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007109:Immunity / Q000502:physiology*; D016867:Immunocompromised Host / Q000187:drug effects*; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D011336:Probability; D020127:Recovery of Function; D012016:Reference Values; D018570:Risk Assessment; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D014606:Uveitis, Anterior / Q000139:chemically induced* / Q000175:diagnosis
chemical_list: D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003596:Cytosine; D000077404:Cidofovir